Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Application of the RecistTM Criteria in Evaluating the Efficacy of Targeted Therapy for Advanced Non-small Cell Lung Cancer With Positive Driving Genes

NCT06142058 is registered in ClinicalTrials.gov with Xueqin Yang as lead sponsor.

NCT NCT06142058
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06142058 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Application of the RecistTM Criteria in Evaluating the Efficacy of Targeted Therapy for Advanced Non-small Cell Lung Cancer With Positive Driving Genes
Lead sponsor
Xueqin Yang
Phase
Observational
Overall status
Recruiting
Start date
November 13, 2023
Completion date
December 31, 2028
Enrollment
44 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

evaluation, nsclc, targeted therapy